Bioject to Participate in World Vaccine Congress – Asia in Singapore June 9-12th
Tigard, OR –May27, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer of
needle-free injection systems announces participation in the World Vaccine Congress - Asia in Singapore
June 9 – 12th. Bioject will be presenting its technology to vaccine company delegates, public health
officials, and developers from throughout the region. Attending the conference will be Mark Logomasini,
President and CEO and Dr. Richard Stout, Executive Vice President and Chief Medical Officer. In
conjunction with the activities at the conference, Bioject will be hosting its first international distributor
meeting.
“We are looking forward to the opportunities this forum provides for Bioject to present and discuss our
technology with senior vaccine attendees across Asia who will be present at this event,” said Mark
Logomasini, Bioject’s President and CEO. “In addition to our presence, our distributors covering all of the
countries, companies, and organizations will also be in attendance at the conference. Their involvement will
help to formulate and execute on strategies to increase awareness and sales in these key markets.”
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-
free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice
held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing
medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with
leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and
government organizations. |
